Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2414-2421

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Talbott, E. O.
Right arrow Articles by Kuller, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Talbott, E. O.
Right arrow Articles by Kuller, L. H.
Related Collections
Right arrow Lipids
Right arrow Obesity
Right arrow Type 2 diabetes
Right arrow Coronary imaging: angiography/ultrasound/Doppler/CC
Right arrow Epidemiology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2414.)
© 2000 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women

Evelyn O. Talbott; David S. Guzick; Kim Sutton-Tyrrell; Kathleen P. McHugh-Pemu; Jeanne V. Zborowski; Karen E. Remsberg; Lewis H. Kuller

From the Department of Epidemiology (E.O.T., K.S.-T., K.P.M.-P., J.V.Z., K.E.R., L.H.K.), University of Pittsburgh, Pittsburgh, Pa, and the Department of Obstetrics/Gynecology (D.S.G.), University of Rochester Medical Center, Rochester, NY.

Abstract—Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder characterized by obesity, hyperandrogenism, and insulin resistance. An adverse lipid profile has also been observed in PCOS-affected women, suggesting that these individuals may be at increased risk for coronary heart disease at a young age. The objective of the present study was to evaluate subclinical atherosclerosis among women with PCOS and age-matched control subjects. A total of 125 white PCOS cases and 142 controls, aged >=30 years were recruited. Collection of baseline sociodemographic data, reproductive hormone levels, and cardiovascular risk factors was conducted from 1992 to 1994. During follow-up (1996 to 1999), these women underwent B-mode ultrasonography of the carotid arteries for the evaluation of carotid intima-media wall thickness (IMT) and the prevalence of plaque. A significant difference was observed in the distribution of carotid plaque among PCOS cases compared with controls: 7.2% (9 of 125) of PCOS cases had a plaque index of >=3 compared with 0.7% (1 of 142) of similarly aged controls (P=0.05). Overall and in the group aged 30 to 44 years, no difference was noted in mean carotid IMT between PCOS cases and controls. Among women aged >=45 years, PCOS cases had significantly greater mean IMT than did control women (0.78±0.03 versus 0.70±0.01 mm, P=0.005). This difference remained significant after adjustment for age and BMI (P<0.05). These results suggest that (1) lifelong exposure to an adverse cardiovascular risk profile in women with PCOS may lead to premature atherosclerosis, and (2) the PCOS-IMT association is explained in part by weight and fat distribution and associated risk factors. There may be an independent effect of PCOS unexplained by the above variables that is related to the hormonal dysregulation of this condition.


Key Words: cardiovascular risk factors • polycystic ovary syndrome • subclinical atherosclerosis • carotid intima-media wall thickness • B-mode duplex ultrasonography




This article has been cited by other articles:


Home page
Hum ReprodHome page
M. Rizzo, K. Berneis, M. Hersberger, I. Pepe, G. Di Fede, G. B. Rini, G. A. Spinas, and E. Carmina
Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype
Hum. Reprod., May 19, 2009; (2009) dep121v1.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A.J. Goverde, A.J.B. van Koert, M.J. Eijkemans, E.A.H. Knauff, H.E. Westerveld, B.C.J.M. Fauser, and F.J. Broekmans
Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria
Hum. Reprod., March 1, 2009; 24(3): 710 - 717.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. M. Hoeger
Polycystic Ovary Syndrome, Inflammation, and Statins: Do We Have the Right Target?
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 35 - 37.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Sathyapalan, E. S. Kilpatrick, A.-M. Coady, and S. L. Atkin
The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 103 - 108.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
Y. Handelsman
Metabolic Syndrome Pathophysiology and Clinical Presentation
Toxicol Pathol, January 1, 2009; 37(1): 18 - 20.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev., December 1, 2008; 29(7): 777 - 822.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Hoeger, K. Davidson, L. Kochman, T. Cherry, L. Kopin, and D. S. Guzick
The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4299 - 4306.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M.I. Ahmed, A.J. Duleba, O. El Shahat, M.E. Ibrahim, and A. Salem
Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome
Hum. Reprod., November 1, 2008; 23(11): 2564 - 2569.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Jensterle, M. Sebestjen, A. Janez, J. Prezelj, T. Kocjan, I. Keber, and M. Pfeifer
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome
Eur. J. Endocrinol., October 1, 2008; 159(4): 399 - 406.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. S. Guzick
Do Cardiovascular Risk Factors in Polycystic Ovarian Syndrome Result in More Cardiovascular Events?
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1170 - 1171.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. J. Shaw, C. N. Bairey Merz, R. Azziz, F. Z. Stanczyk, G. Sopko, G. D. Braunstein, S. F. Kelsey, K. E. Kip, R. M. Cooper-DeHoff, B. D. Johnson, et al.
Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health--National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1276 - 1284.
[Abstract] [Full Text] [PDF]


Home page
Nutr Clin PractHome page
G. U. Liepa, A. Sengupta, and D. Karsies
Polycystic Ovary Syndrome (PCOS) and Other Androgen Excess-Related Conditions: Can Changes in Dietary Intake Make a Difference?
Nutr Clin Pract, February 1, 2008; 23(1): 63 - 71.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. E. Nestler
Metformin for the Treatment of the Polycystic Ovary Syndrome
N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Sattar and S. M. Nelson
Polycystic Ovarian Syndrome, Biomarkers, and Metformin: Research, Risk, and Reality
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 34 - 36.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Shroff, A. Kerchner, M. Maifeld, E. J. R. Van Beek, D. Jagasia, and A. Dokras
Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4609 - 4614.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Luque-Ramirez, C. Mendieta-Azcona, F. Alvarez-Blasco, and H. F. Escobar-Morreale
Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome
Hum. Reprod., December 1, 2007; 22(12): 3197 - 3203.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
O. Celik, I. Sahin, N. Celik, S. Hascalik, L. Keskin, H. Ozcan, A. Uckan, and F. Kosar
Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study
Hum. Reprod., November 1, 2007; 22(11): 2992 - 2998.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
R. S. Legro
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
JAMA, February 7, 2007; 297(5): 509 - 519.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Banaszewska, L. Pawelczyk, R. Z. Spaczynski, J. Dziura, and A. J. Duleba
Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 456 - 461.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Berneis, M. Rizzo, V. Lazzaroni, F. Fruzzetti, and E. Carmina
Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 186 - 189.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M.-J. Chen, W.-S. Yang, J.-H. Yang, C. K. Hsiao, Y.-S. Yang, and H.-N. Ho
Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS
Hum. Reprod., September 1, 2006; 21(9): 2266 - 2271.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S. Topcu, M. Caliskan, E. E. Ozcimen, D. Tok, A. Uckuyu, D. Erdogan, H. Gullu, A. Yildirir, H. Zeyneloglu, and H. Muderrisoglu
Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease?
Hum. Reprod., April 1, 2006; 21(4): 930 - 935.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. C. Lewandowski, J. Komorowski, C. J. O'Callaghan, B. K. Tan, J. Chen, G. M. Prelevic, and H. S. Randeva
Increased Circulating Levels of Matrix Metalloproteinase-2 and -9 in Women with the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1173 - 1177.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, F. Manguso, S. Savastano, T. Russo, A. Tolino, F. Zullo, G. Lombardi, et al.
Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6072 - 6076.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Lakhani, A. Leonard, A.M. Seifalian, and P. Hardiman
Microvascular dysfunction in women with polycystic ovary syndrome
Hum. Reprod., November 1, 2005; 20(11): 3219 - 3224.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Meyer, B. P. McGrath, and H. J. Teede
Overweight Women with Polycystic Ovary Syndrome Have Evidence of Subclinical Cardiovascular Disease
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5711 - 5716.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Kravariti, K. K. Naka, S. N. Kalantaridou, N. Kazakos, C. S. Katsouras, A. Makrigiannakis, E. A. Paraskevaidis, G. P. Chrousos, A. Tsatsoulis, and L. K. Michalis
Predictors of Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5088 - 5095.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
B. Vural, E. Caliskan, E. Turkoz, T. Kilic, and A. Demirci
Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome
Hum. Reprod., September 1, 2005; 20(9): 2409 - 2413.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Meyer, B. P. McGrath, J. Cameron, D. Kotsopoulos, and H. J. Teede
Vascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4630 - 4635.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy
Diabetes Care, July 1, 2005; 28(7): 1821 - 1830.
[Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. B. Kilicdag, T. Bagis, E. Tarim, E. Aslan, S. Erkanli, E. Simsek, B. Haydardedeoglu, and E. Kuscu
Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial
Hum. Reprod., June 1, 2005; 20(6): 1521 - 1528.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
E Diamanti-Kandarakis, K Alexandraki, A Protogerou, C Piperi, C Papamichael, A Aessopos, J Lekakis, and M Mavrikakis
Metformin administration improves endothelial function in women with polycystic ovary syndrome
Eur. J. Endocrinol., May 1, 2005; 152(5): 749 - 756.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou
Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. Vrbikova and D. Cibula
Combined oral contraceptives in the treatment of polycystic ovary syndrome
Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Sutton-Tyrrell, R. P. Wildman, K. A. Matthews, C. Chae, B. L. Lasley, S. Brockwell, R. C. Pasternak, D. Lloyd-Jones, M. F. Sowers, J. I. Torrens, et al.
Sex Hormone-Binding Globulin and the Free Androgen Index Are Related to Cardiovascular Risk Factors in Multiethnic Premenopausal and Perimenopausal Women Enrolled in the Study of Women Across the Nation (SWAN)
Circulation, March 15, 2005; 111(10): 1242 - 1249.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A S T Bickerton, N Clark, D Meeking, K M Shaw, M Crook, P Lumb, C Turner, and M H Cummings
Cardiovascular risk in women with polycystic ovarian syndrome (PCOS)
J. Clin. Pathol., February 1, 2005; 58(2): 151 - 154.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
V. Sepilian and M. Nagamani
Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 60 - 65.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. O. Talbott, J. V. Zborowski, M. Y. Boudreaux, K. P. McHugh-Pemu, K. Sutton-Tyrrell, and D. S. Guzick
The Relationship between C-Reactive Protein and Carotid Intima-Media Wall Thickness in Middle-Aged Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6061 - 6067.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. O. Talbott, J. V. Zborowski, J. R. Rager, M. Y. Boudreaux, D. A. Edmundowicz, and D. S. Guzick
Evidence for an Association between Metabolic Cardiovascular Syndrome and Coronary and Aortic Calcification among Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5454 - 5461.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. Tarkun, B. C. Arslan, Z. Canturk, E. Turemen, T. Sahin, and C. Duman
Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome: Relationship with Insulin Resistance and Low-Grade Chronic Inflammation
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5592 - 5596.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, S. Di Biase, T. Russo, D. Labella, F. Zullo, G. Lombardi, and A. Colao
Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4588 - 4593.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. S. Guzick
Cardiovascular Risk in PCOS
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3694 - 3695.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao
The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
R. S. Legro, E. Myers, and for the Reproductive Medicine Network
Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?
Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Taponen, H. Martikainen, M.-R. Jarvelin, U. Sovio, J. Laitinen, A. Pouta, A.-L. Hartikainen, M. I. McCarthy, S. Franks, M. Paldanius, et al.
Metabolic Cardiovascular Disease Risk Factors in Women with Self-Reported Symptoms of Oligomenorrhea and/or Hirsutism: Northern Finland Birth Cohort 1966 Study
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2114 - 2118.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Boulman, Y. Levy, R. Leiba, S. Shachar, R. Linn, O. Zinder, and Z. Blumenfeld
Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2160 - 2165.
[Abstract] [Full Text] [PDF]


Home page
Biol Res NursHome page
M. Littleton-Kearney and P. D. Hurn
Testosterone as a Modulator of Vascular Behavior
Biol Res Nurs, April 1, 2004; 5(4): 276 - 285.
[Abstract] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Definitions of the Insulin Resistance Syndrome: The 1st World Congress on the Insulin Resistance Syndrome
Diabetes Care, March 1, 2004; 27(3): 824 - 830.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. F. Escobar-Morreale, J. I. Botella-Carretero, G. Villuendas, J. Sancho, and J. L. San Millan
Serum Interleukin-18 Concentrations Are Increased in the Polycystic Ovary Syndrome: Relationship to Insulin Resistance and to Obesity
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 806 - 811.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
M. T. Sheehan
Polycystic Ovarian Syndrome: Diagnosis and Management
Clin. Med. Res., February 1, 2004; 2(1): 13 - 27.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
Hum. Reprod., January 1, 2004; 19(1): 41 - 47.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
The Endocrine Society Meeting: Topics in Insulin Sensitivity and Hypertension
Diabetes Care, September 1, 2003; 26(9): 2679 - 2688.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. S. Legro
Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?
Endocr. Rev., June 1, 2003; 24(3): 302 - 312.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler
A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
F. C. W. Wu and A. von Eckardstein
Androgens and Coronary Artery Disease
Endocr. Rev., April 1, 2003; 24(2): 183 - 217.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Orio Jr., S. Palomba, S. Di Biase, A. Colao, L. Tauchmanova, S. Savastano, D. Labella, T. Russo, F. Zullo, and G. Lombardi
Homocysteine Levels and C677T Polymorphism of Methylenetetrahydrofolate Reductase in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 673 - 679.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Taponen, H. Martikainen, M.-R. Jarvelin, J. Laitinen, A. Pouta, A.-L. Hartikainen, U. Sovio, M. I. McCarthy, S. Franks, and A. Ruokonen
Hormonal Profile of Women with Self-Reported Symptoms of Oligomenorrhea and/or Hirsutism: Northern Finland Birth Cohort 1966 Study
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 141 - 147.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. S. Randeva, K. C. Lewandowski, J. Drzewoski, K. Brooke-Wavell, C. O'Callaghan, L. Czupryniak, E. W. Hillhouse, and G. M. Prelevic
Exercise Decreases Plasma Total Homocysteine in Overweight Young Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4496 - 4501.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Seli and A. J. Duleba
Should patients with polycystic ovarian syndrome be treated with metformin?
Hum. Reprod., September 1, 2002; 17(9): 2230 - 2236.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. O. Yildiz, I. C. Haznedaroglu, S. Kirazli, and M. Bayraktar
Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic State
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3871 - 3875.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J. E. Nestler
Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement
Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. G. Solomon, F. B. Hu, A. Dunaif, J. E. Rich-Edwards, M. J. Stampfer, W. C. Willett, F. E. Speizer, and J. E. Manson
Menstrual Cycle Irregularity and Risk for Future Cardiovascular Disease
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2013 - 2017.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. S. Legro, R. Bentley-Lewis, D. Driscoll, S. C. Wang, and A. Dunaif
Insulin Resistance in the Sisters of Women with Polycystic Ovary Syndrome: Association with Hyperandrogenemia Rather Than Menstrual Irregularity
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2128 - 2133.
[Abstract] [Full Text] [PDF]


Home page
JWatch Women's HealthHome page
Chronic Hyperandrogenic Anovulation and Premature Atherosclerosis
Journal Watch Women's Health, January 9, 2001; 2001(109): 6 - 6.
[Full Text]